Abstract
Evidence presented in 2011 suggests that rheumatoid arthritis might comprise two separate diseases—each with different etiological underpinnings—and that kinase inhibitors could soon be added to the therapeutic armamentarium. Together with new definitions of remission, these advances could aid the development of personalized, treat-to-target strategies.
MeSH terms
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / diagnosis*
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / etiology
-
Humans
-
Protein Kinase Inhibitors / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Remission Induction
-
Terminology as Topic*
-
Treatment Outcome
Substances
-
Antirheumatic Agents
-
Protein Kinase Inhibitors
-
Protein-Tyrosine Kinases